Loading
CT
Cerevel Therapeutics Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Koppel Adam, was filed 18 Oct 2023.
Cerevel Therapeutics Holdings, Inc.: what insiders have been doing
Cerevel Therapeutics Holdings, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Cerevel Therapeutics Holdings, Inc. has published a filing in the past twelve months. The most recent one dates from 5 August 2024.
Over the whole record (from 2020), the tally stands at 17 purchases and 80 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
243
Thresholds
n/a
Buy Volume
€323M
17 ops. · all time
Sell Volume
€59M
80 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Net income-US$372.7M
Last declaration on 5 August 2024
Declarations243 total
10,461 sharesCommon StockSEC:0000950170-24-090815:1
402,326 sharesCommon StockSEC:0000950170-24-090815:2
10,461 sharesCommon StockSEC:0000950170-24-090908:1
65,679,781 sharesCommon StockSEC:0000950170-24-090908:2
10,290 sharesCommon StockSEC:0000950170-24-090789:1
83,857 sharesCommon StockSEC:0000950170-24-090851:1
10,461 sharesCommon StockSEC:0000950170-24-090853:1
10,461 sharesCommon StockSEC:0000950170-24-090833:1
10,461 sharesCommon StockSEC:0000950170-24-090790:1
10,461 sharesCommon StockSEC:0000950170-24-090806:1
10,461 sharesCommon StockSEC:0000950170-24-090842:1
10,461 sharesCommon StockSEC:0000950170-24-090903:1
65,679,781 sharesCommon StockSEC:0000950170-24-090903:2
27,349,211 shares@ US$45.00100.0% of flowCommon StockSEC:0000078003-24-000169:0
31,822 sharesCommon StockSEC:0000950170-24-090815:0
3,282 sharesCommon StockSEC:0000950170-24-090842:0
6,370 sharesCommon StockSEC:0000950170-24-090830:0
45,727 sharesCommon StockSEC:0000950170-24-090787:0
160,452 sharesCommon StockSEC:0000950170-24-090851:0
25,042 sharesCommon StockSEC:0000950170-24-090827:0
46,092 sharesCommon StockSEC:0000950170-24-090806:0
16,913 sharesCommon StockSEC:0000950170-24-090813:0
15,638 sharesCommon StockSEC:0000950170-24-090789:0
3,282 sharesCommon StockSEC:0000950170-24-090908:0
14,673 sharesCommon StockSEC:0000950170-24-090861:0
25 of 243 declarations
About Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. was a United States-based biopharmaceutical company formerly listed on the NASDAQ market. It was focused on neuroscience, with a particular emphasis on central nervous system disorders such as schizophrenia, Parkinson’s disease, and other psychiatric or neurological conditions. The company was founded in 2018, emerging from assets originally associated with Pfizer, and it established its headquarters in Cambridge, Massachusetts, a leading U.S. biotech hub.
Cerevel’s business model was that of a development-stage biotechnology company: it was centered on research, preclinical work, and clinical trials rather than on a mature commercial product base. Its pipeline was built around a handful of high-profile neuroscience candidates. The most closely watched programs included emraclidine, an oral next-generation antipsychotic being studied in schizophrenia, and tavapadon, a once-daily candidate for Parkinson’s disease. The company also advanced additional neuroscience assets aimed at improving treatment options in areas where current standards of care can be limited by efficacy or tolerability challenges.
Read moreShow less
From a competitive standpoint, Cerevel operated as a focused specialty biotech in a highly demanding segment of the pharmaceutical industry. Its strategic value came from the perceived quality of its pipeline and the potential for differentiated clinical data, rather than from current revenue generation. In that sense, Cerevel represented a classic high-risk/high-reward neuroscience platform: substantial research and development spending, limited near-term commercial visibility, and significant dependence on clinical milestones. The company competed indirectly with large multinational pharmaceutical groups, as well as with smaller biotech peers pursuing new mechanisms in psychiatry and neurology.
A major recent development reshaped the investment case. AbbVie announced in December 2023 that it would acquire Cerevel, and the transaction was completed on August 1, 2024. As a result, Cerevel no longer trades as an independent public company; it has been integrated into AbbVie. For investors in France, Belgium, and Switzerland, Cerevel is therefore best viewed today as a historical NASDAQ-listed neuroscience biotech rather than an ongoing standalone equity story. Its legacy remains relevant mainly through the assets AbbVie inherited, especially emraclidine and tavapadon, which were central to the rationale for the acquisition.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
